Teclistamab Study for Multiple Myeloma: This study looks at how the body processes a drug called teclistamab, which is used for treating relapsed or refractory multiple myeloma, a type of blood cancer. The study compares teclistamab made in two different ways. Multiple myeloma is a condition where abnormal plasma cells build up in the bone marrow and interfere with the production of normal blood cells.
- Length of Study: Participants must have received 1 to 3 previous treatments for multiple myeloma.
- Visits Needed: Participants will have several check-ups during the study, including pregnancy tests for women who can have children.
- Eligibility: Participants should have a confirmed diagnosis of multiple myeloma and meet specific health and treatment history criteria.
Note: Participants must not have had certain treatments before, like CAR-T cell therapy, and must not have serious allergies to study drugs. If you have had certain vaccines recently or plan to have major surgery soon, you may not be eligible. Always discuss with your healthcare provider to see if this study is a good fit for you.
How understandable was the trial content above?
Hard to understand
Easy to understand